Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1
Recruiting
- Conditions
- Head and Neck CarcinomaAdenoid Cystic CarcinomaLung CancerNon-Small Cell Lung CancerBreast CancerPancreatic CancerMesotheliomaThymic CarcinomaCervical CancerOvarian Cancer
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- VM Oncology, LLC
- Target Recruit Count
- 82
- Registration Number
- NCT03556228
- Locations
- 🇺🇸
Providence Medical Foundation (site 209), Santa Rosa, California, United States
🇺🇸Hartford Hospital (site 210), Hartford, Connecticut, United States
🇺🇸The George Washington University Cancer Center (site 212), Washington, District of Columbia, United States
© Copyright 2025. All Rights Reserved by MedPath